Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avidity Biosciences (RNA) Change in Acquisitions & Divestments: 2021-2025

Historic Change in Acquisitions & Divestments for Avidity Biosciences (RNA) over the last 4 years, with Sep 2025 value amounting to $269.6 million.

  • Avidity Biosciences' Change in Acquisitions & Divestments rose 90.20% to $269.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.1 billion, marking a year-over-year increase of 141.42%. This contributed to the annual value of $586.4 million for FY2024, which is 74.96% up from last year.
  • According to the latest figures from Q3 2025, Avidity Biosciences' Change in Acquisitions & Divestments is $269.6 million, which was up 2.56% from $262.8 million recorded in Q2 2025.
  • Avidity Biosciences' Change in Acquisitions & Divestments' 5-year high stood at $330.2 million during Q1 2025, with a 5-year trough of $3.0 million in Q4 2021.
  • Its 3-year average for Change in Acquisitions & Divestments is $162.2 million, with a median of $109.7 million in 2024.
  • Data for Avidity Biosciences' Change in Acquisitions & Divestments shows a peak YoY skyrocketed of 2,657.67% (in 2022) over the last 5 years.
  • Quarterly analysis of 5 years shows Avidity Biosciences' Change in Acquisitions & Divestments stood at $3.0 million in 2021, then soared by 2,657.67% to $82.7 million in 2022, then increased by 27.78% to $105.7 million in 2023, then surged by 123.96% to $236.7 million in 2024, then soared by 90.20% to $269.6 million in 2025.
  • Its Change in Acquisitions & Divestments stands at $269.6 million for Q3 2025, versus $262.8 million for Q2 2025 and $330.2 million for Q1 2025.